Ovarian and Breast Cancer
We recommend
Targeting HER2 is Clinically Meaningful Even with Its Low Expression
Distinguishing HER2 receptor expression status on the surface of breast cancer tumor cells as simply positive or negative is now proving insufficient. Ultimately, it can lead to the non-administration of effective targeted therapy. What do we actually know about the “gray zone” between HER2 positivity and negativity?
Trastuzumab Deruxtecan in Patients with HER2+ Metastatic Breast Cancer
Last year, results of studies published in the Lancet journal demonstrated a significant clinical…
Current Sequence of Treatment for Metastatic HER2+ Breast Cancer
In September 2023, experts from Miami Cancer Institute published their consensus statement on the…
No content is currently available on this topic.
Subscribe
Most read on this topic
Journal on this topic
Related topic
Interesting links
Most read on this topic
- Current Sequence of Treatment for Metastatic HER2+ Breast Cancer
- Targeting HER2 is Clinically Meaningful Even with Its Low Expression
- Trastuzumab Deruxtecan in Patients with HER2+ Metastatic Breast Cancer
Journal on this topic
Related topic
Interesting links